wehewehe
ʻO kā mākou 4-amino-5-methyl-2-hydroxypyridine kahi mea koʻikoʻi i ka synthesis o Finerenone, kahi mea kūʻē hou non-steroidal selective mineralocorticoid receptor antagonist me ka hiki ke mālama i nā maʻi cardiovascular a me ka renal.Nā noi kūpono.He mea koʻikoʻi kēia hui i ka hana ʻana o Finerenone, e lilo ia i mea waiwai nui no nā hui lāʻau lapaʻau a me nā keʻena noiʻi.
ʻO ka maʻemaʻe a me ka maikaʻi o kā mākou 4-amino-5-methyl-2-hydroxypyridine he mea likeʻole, e hōʻoia ana i kona kūpono no nā pae a pau o ka hoʻomohalaʻana i ka lāʻau a me ka hanaʻana.Me ka nānā ʻana i ka maikaʻi a me ka hana hou, ua hoʻomaikaʻi mākou i kā mākou synthesis a me nā kaʻina hoʻomaʻemaʻe e hāʻawi i nā huahana e kū i nā kūlana koʻikoʻi o ka ʻoihana lāʻau.
ʻO kā mākou kūpaʻa i ka maikaʻi e hoʻonui i kēlā me kēia ʻano o kā mākou hana, mai ka loaʻa ʻana o nā mea waiwai a hiki i ka hana ʻana a me ka hāʻawi ʻana.Hoʻopili mākou i nā kūlana palekana kiʻekiʻe a me ka hoʻokō pono e hōʻoia i kā mākou mea kūʻai aku e loaʻa nā huahana i kūpono i nā koi hoʻoponopono koʻikoʻi.
E koho iā mākou
Loaʻa iā JDK nā hale hana papa mua a me nā lako hoʻokele maikaʻi, e hōʻoiaʻiʻo ana i ka lako paʻa o nā kikowaena API.Hōʻoia ka hui ʻoihana i ka R&D o ka huahana.E kūʻē i nā mea ʻelua, ke ʻimi nei mākou iā CMO & CDMO ma ka mākeke kūloko a me ka honua.
